KLRS insider transaction filings
Kalaris Therapeutics, Inc. — 36 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-28. Screen KLRS transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 3 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 3.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Bayko Liisa Ann — Chief Financial Officer | 1 | — | — | 1 |
| KEATING LAURIE — Director | 1 | — | — | 1 |
| Vandekop Amy O'Leary — VP, Corporate Controller | 1 | — | — | 1 |
Recent Form 4 filings — Kalaris Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-28 | 4 | Vandekop Amy O'Leary — VP, Corporate Controller | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-08-03 | 4 | KEATING LAURIE — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Bayko Liisa Ann — Chief Financial Officer | Grant/award (A): 220,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Ferrara Napoleone — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Dybbs Michael — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Jovan-Embiricos Morana — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Hallal David — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | ADAMIS ANTHONY P — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | AKKARAJU SRINIVAS — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | PATTERSON LEONE D — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | AKKARAJU SRINIVAS — Director, 10% owner Samsara BioCapital, L.P. — 10% owner Samsara BioCapital GP, LLC — 10% owner Samsara Opportunity Fund, L.P. — 10% owner Samsara Opportunity Fund GP, LLC — 10% owner | Purchase (P): 244,300 @ $4.83 · Other (J): 66,906 @ $0 · Other (J): 14,937 @ $0 · Other (J): 4,471 @ $0 | EDGAR |
| 2026-03-23 | 4 | Hagen Brett R — Chief Accounting Officer | Sale (S): 1,915 @ $6.72 · Grant/award (A): 60,800 (derivative) @ $0 | EDGAR |
| 2026-03-20 | 4 | Oxtoby Andrew — See Remarks, Director | Grant/award (A): 222,000 (derivative) @ $0 | EDGAR |
| 2026-03-20 | 4 | Gall Matthew — Chief Financial Officer | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2026-03-20 | 4 | Feinsod Matthew — Chief Medical Officer | Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | AKKARAJU SRINIVAS — Director, 10% owner Samsara BioCapital, L.P. — 10% owner Samsara BioCapital GP, LLC — 10% owner Samsara Opportunity Fund, L.P. — 10% owner Samsara Opportunity Fund GP, LLC — 10% owner | Purchase (P): 479,847 @ $10.42 | EDGAR |
| 2025-12-22 | 4 | AKKARAJU SRINIVAS — Director, 10% owner Samsara Opportunity Fund, L.P. — 10% owner Samsara Opportunity Fund GP, LLC — 10% owner | Grant/award (A): 1,500,000 @ $10 | EDGAR |
| 2025-11-03 | 4 | Gall Matthew — Chief Financial Officer | Grant/award (A): 235,000 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | Oxtoby Andrew — See Remarks, Director | Grant/award (A): 287,000 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | Ferrara Napoleone — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | Feinsod Matthew — Chief Medical Officer | Grant/award (A): 70,551 (derivative) @ $0 · Grant/award (A): 101,000 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | Hagen Brett R — Chief Accounting Officer | Grant/award (A): 50,262 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | Dybbs Michael — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | Jovan-Embiricos Morana — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | Hallal David — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | PATEL SAMIR CHANDRAKANT — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | ADAMIS ANTHONY P — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | AKKARAJU SRINIVAS — Director, 10% owner | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | PATTERSON LEONE D — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2025-03-27 | 4 | Hagen Brett R — Chief Accounting Officer | Sale (S): 907 @ $8.97 | EDGAR |
| 2025-03-18 | 4 | Oxtoby Andrew — See Remarks, Director | Grant/award (A): 476,611 (derivative) | EDGAR |
| 2025-03-18 | 4 | Ferrara Napoleone — Director | Grant/award (A): 504,000 | EDGAR |
| 2025-03-18 | 4 | Feinsod Matthew — Chief Medical Officer | Grant/award (A): 4,030 · Grant/award (A): 28,224 (derivative) | EDGAR |
| 2025-03-18 | 4 | PATEL SAMIR CHANDRAKANT — Director | Grant/award (A): 252,000 · Grant/award (A): 100,800 · Grant/award (A): 105,913 (derivative) | EDGAR |
| 2025-03-18 | 4 | ADAMIS ANTHONY P — Director | Grant/award (A): 19,484 (derivative) · Grant/award (A): 12,989 (derivative) | EDGAR |
| 2025-03-18 | 4 | AKKARAJU SRINIVAS — Director, 10% owner | Grant/award (A): 11,444,503 | EDGAR |
Recent 8-K events — Kalaris Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-17 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-17 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=KLRS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →